The 2025 CANMAT guideline updates first-, second-, and third-line treatments for major depressive disorder (MDD), emphasizing measurement-based care, sequenced treatment, and the growing role of ketamine, esketamine, and augmentation strategies for treatment-resistant depression.
“Major Depressive Disorder: 2025 CANMAT Treatment Guideline” is part of iMedCompanion’s plain-language library for international patients travelling to China for care. It explains what usually happens, what to prepare, and where to find related specialists and hospitals.
No. It explains what usually happens so you can ask better questions; decisions are made with your own specialist.
The guides are published in English; interpretation and translation are arranged as a separate service.
Each guide links to related specialists and hospitals, or you can send an enquiry and a medical advisor will match you.
The difference between Hodgkin and non-Hodgkin lymphoma, how staging and subtype decide treatment, the standard regimens, and what…
Why bleeding into the brain while on anticoagulants or antiplatelets is different, how clotting is reversed, when surgery is considered,…
Takayasu arteritis is a chronic inflammation of the aorta in young women. The 2025 Chinese guideline stresses early recognition, steroids,…
